We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Immunodiagnostic Systems Showcases Next-Gen Immunoanalyzer at AACC

By LabMedica International staff writers
Posted on 31 Jul 2018
Immunodiagnostic Systems (Tyne & Wear, UK) showcased its next generation immunoanalyzer, the IDS-i10, at the AACC annual meeting and exhibition, the world’s largest scientific conference and tradeshow in the laboratory medicine field. More...
This year marked the 70th edition of the scientific meeting and clinical lab expo, hosted in McCormick Place, in Chicago, USA.

The exhibition provided a platform to connect with the world’s thought leaders in breaking laboratory medicine operating in fields, including clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine and lab management. The tradeshow was full of technological advances as over 200 new product introductions were unveiled and demonstrated. Additionally, research developments and changes in the laboratory medicine field were discussed in a variety of clinical areas through an educational experience, which could be tailored by selecting from a range of scientific sessions.

Immunodiagnostic Systems is a provider of in-vitro diagnostic solution to the clinical laboratory market. The company develops, manufactures and markets immunoassays and automated immunoanalyzer technologies to provide improved diagnostic outcomes for patients. Its immunoassay portfolio is a combination of an endocrinology specialty-testing menu and assay panels in complementary fields.

At AACC 2018, Immunodiagnostic Systems showcased its new IDS-i10 immunoanalyzer with faster testing capability and the capacity to connect to laboratory track systems. The instrument is designed to help medical professionals perform automated immunoassays more efficiently than ever. The company also discussed its automated and manual assay panels, with its experts available at the event to assist with queries from the attendees.

Related Links:
Immunodiagnostic Systems


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.